In Focus
Waking the Giant: Business Model Innovation in the Drug Industry
Contrary to common belief, the decline of pharma’s traditional model is not imminent, it has happened already -- as illustrated by the industry’s weak performance in total shareholder return (TSR). Pharmaceutical companies need to fundamentally rethink their business models.
» view PDF
Recent Publications
Collateral Damage Industry Focus:
Implications of the Financial Crisis for the Biopharmaceutical Sector
The financial crisis is no longer just a financial crisis--it has spread to the wider economy.
» read more
Health Care and the 2008 Election:
Revolution, Reform, or Return to Business as Usual?
Having surveyed 1,200 health care executives from across the pharmaceutical, medical technologies, provider, and payer sectors, BCG assessed prospects for revenue growth, innovation, and costs under an Obama or a McCain administration.
» read more
Health Care
In Health Care today, scientific and technological frontiers are expanding at unprecedented rates – even as economic and financial pressures shrink profit margins, intensify competition, and constrain the funds available for investment.
Radical shifts are transforming how science understands and treats disease; how Health Care players specialize, partner, and compete; and the many ways patients increasingly view their role as consumers of their own health care. Consequently, health care players throughout the industry must confront difficult choices.
The players – the developers, manufacturers, and distributors of health care products as well as the payers and the providers that deliver health care services – that take aggressive steps now will find themselves better positioned for survival and ultimately success in the years ahead.
BCG's Health Care practice enjoys a long tradition of pioneering new concepts and formulating novel business strategies. This tradition began in the 1980s, when our work on disease management helped define an approach to Health Care delivery that broke the compromise between cost effectiveness and improved outcomes.
It has continued through our comprehensive examination of the future of the biopharmaceutical industry and the impact of changing technologies on business realities and strategy in the Health Care industry. Today it is manifest in our exploration of whether R&D productivity in the biopharmaceutical sector can be enhanced, our work with clients in the increasingly critical area of pharmaceutical sales and marketing, and other work.
Our broad base of clients includes institutions across the entire spectrum of the Health Care industry, including the world's major pharmaceutical and biotech companies, producers of medical devices and technology, payers, and providers. Whether working with drug companies, technology players, national health systems, managed care organizations, academic medical centers, or hospitals, we share with all our clients the same deep insights into the business of health care and the same commitment to excellent results.
